Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Adult Congenital Heart Disease Workforce Challenges in the United States: Current State and Future Needs: Proceedings from the American College of Cardiology (ACC), Adult Congenital Pediatric Cardiology (ACPC) Council Adult Congenital Heart Disease Summit

Zaidi AN, Sachdeva R, Kovacs R, Franklin WJ, Gurvitz M, Ermis P, Awerbach JD, Weissman G, Bradley E, Cox D, Daniels CJ, Gregg D 4th,[...]

Longitudinal Data from the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not: JACC Adv. 2025;4(7):101686

Soto-Mota A, Norwitz NG, Manubolu VS, Kinninger A, Wood TR, Earls J, Feldman D, Budoff M. Longitudinal Data from the KETO-CTA Study: Plaque Predicts Plaque,[...]

Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right Atrial Rupture

Makaroff KE, Hampilos K, Sayed S, Emert B, Hu X, Nsair A, Kwon M, Middlekauff H. Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right[...]